Moreover, similar findings were observed in a prodromal AD sample, where p-tau217 had a higher accuracy in identifying amyloid positivity in patients with mild cognitive impairment (MCI) or those who will progress to AD dementia when compared to the other plasma phospho-epitopes of tau [17]. This evidence concerns the gene MAPT and Alzheimer disease.